Peptide record

TPDB05074

Antibacterial Antiviral Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05074
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0
standard
No
A 24-aa standard natural multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, AI4AVP, and other sources, with an available 3D structural model.
Sequence
GLRSRIWLWVLLMIWQESNRFKRM
Physicochemical Analysis
C145H228N42O31S2
ADCHPTY
RL
3119.79
12.41
5
1
13
+4
-2.41
-0.088
109.58
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
16500
528.88
4
Residue Composition
number
0
A
4
R
1
N
0
D
0
C
1
E
1
Q
1
G
0
H
2
I
4
L
1
K
2
M
1
F
0
P
2
S
0
T
3
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 4 N: 1 D: 0 C: 0 E: 1 Q: 1 G: 1 H: 0 I: 2 L: 4 K: 1 M: 2 F: 1 P: 0 S: 2 T: 0 W: 3 Y: 0 V: 1
Chemical Descriptors
24
C145H228N42O31S2
3119.79
12.41
+4
-2.41
-0.088
Evidence Records 4 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

NA

Other

inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 1.25 uM).
Evidence 2 Activity

Activity

Antiviral

Source & Reference

dbAMP 3.0 DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
dbAMP 3.0 classified under the Anti-viral function class.
inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 1.25 uM).
Evidence 3 Activity

Activity

50% Cell death
Toxicity
>32.1 µM
Cytotoxic
50% Cell death | >32.1 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
Cytotoxicity: [Ref.20086159]CEM-SS cells:TC50(cause 50% Cell death) >32.1 µM.

Source & Reference

NA
DRAMP
Antimicrob Agents Chemother. 2010 Mar 54(3):1343-6.